Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor

Journal of Nuclear Medicine

Volumn 46, Issue 4, 2005, Pages 675-682

  Zhao, Songji ^a   Kuge, Yuji ^a   Mochizuki, Takafumi ^b   Takahashi, Toshiyuki ^c   Nakada, Kunihiro ^a   Sato, Masayuki ^a   Takei, Toshiki ^a   Tamaki, Nagara ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Nikko Memorial Hospital   (Japan)

^c Hokkaido Gastroenterology Hospital   (Japan)

Author keywords

18F FDG; Glucose; Heterogeneity; Hexokinase; Transporters; Tumor

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; DIAGNOSTIC AGENT; GLUCOSE TRANSPORTER; NERVE PROTEIN; RADIOPHARMACEUTICAL AGENT; SLC2A1 PROTEIN, RAT; SLC2A3 PROTEIN, RAT; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTORADIOGRAPHY; CELL HETEROGENEITY; CELLULAR DISTRIBUTION; COMPUTER ASSISTED TOMOGRAPHY; HEPATOMA CELL; HISTOCHEMISTRY; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; ANIMAL; EVALUATION; GENE EXPRESSION PROFILING; LIVER CELL CARCINOMA; METABOLISM; METHODOLOGY; SCINTISCANNING; STATISTICS; TUMOR CELL LINE; WISTAR RAT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION PROFILING; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HEXOKINASE; MALE; MONOSACCHARIDE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; STATISTICS; TUMOR MARKERS, BIOLOGICAL;

EID: 19644398382     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999;40:1784-1791.
2. Higashi T, Sakahara H, Torizuka T, et al. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med. 1999; 40:1424-1433.
3. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-1695.
4. 18F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med. 2002;43:510-518.
5. Haberkorn U, Ziegler SI, Oberdorfer F, et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol. 1994;21:827-834.
6. Golshani-Hebroni SG, Bessman SP. Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J Bioenerg Biomembr. 1997;29:331-338.
7. Bell GI, Burant CF, Takeda J, Gould GW. Structure and function of mammalian facilitative sugar transporters. J Biol Chem. 1993;268:19161-19164.
8. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999;40:556-565.
9. Reske SN, Grillenberger KG, Glatting G, et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med. 1997;38:1344-1348.
10. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer. 1993;72:2979-2985.
11. Boado RJ, Black KL, Pardridge WM. Gene expression of Glut-3 and Glut-1 glucose transporters in human brain tumors. Brain Res Mol Brain Res. 1994;27: 51-57.
12. Younes M, Brown RW, Stephenson M, Gondo M, Cagle PT. Overexpression of Glut-1 and Glut-3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 1997;80:1046-1051.
13. Suzuki T, Iwazaki A, Katagiri H, et al. Enhanced expression of glucose transporter Glut-3 in tumorigenic HeLa cell hybrids associated with tumor suppressor dysfunction. Eur J Biochem. 1999;262:534-540.
14. Aloj L, Caracó C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res. 1999;59:4709-4714.
15. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
16. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18- fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104-112.
17. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma. I. Are inflammatory cells important? J Nucl Med. 1995;36:1854-1861.
18. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Active and passive mechanisms of [fluorine-18]fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study. J Nucl Med. 1994;35:1067-1075.
19. Kubota R, Kubota K, Yamada S, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med. 1995;36:484-492.
20. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med. 1997;38:280-287.
21. Zhao S, Kuge Y, Tsukamoto E, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med. 2001;28:730-735.
22. 18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Nucl Med Biol. 1990;17: 273-279.
23. Zhao S, Kuge Y, Tsukamoto E, et al. Fluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loading. Nucl Med Commun. 2002;23:545-550.
24. 14C-DG autoradiography. J Nucl Med. 2004;45:1398-1405.
25. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002;43:173-180.
26. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999;59: 5830-5835.
27. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J Nucl Med. 1997;38:1337-1344.
28. Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med. 2001;42:1551-1555.
29. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst. 2001;93:309-314.
30. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med. 1996;37:1042-1047.
31. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci. 1999;24:68-72.
32. Clavo AC, Brown RS, Wahl RL. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995;36:1625-1632.
33. Dearling JL, Flynn AA, Sutcliffe-Goulden J, et al. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med. 2004;45:101-107.
34. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science. 1987;235:1492-1495.
35. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. Science. 1987;235:1495-1498.
36. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000;57:170-178.
37. Bell HS, Whittle IR, Walker M, Leaver HA, Wharton SB. The development of necrosis and apoptosis in glioma: experimental findings using spheroid culture systems. Neuropathol Appl Neurobiol. 2001;27:291-304.
38. 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387.
39. 18F]-D-glucose. Cancer. 1998;82:2227-2234.
40. Lucignani G, Jereczek-Fossa BA, Orecchia R. The role of molecular imaging in precision radiation therapy for target definition, treatment planning optimisation and quality control. Eur J Nucl Med Mol Imaging. 2004;31:1059-1063.